ERBB2 and breast carcinoma: Regarding the 21.57% of cases of mutated P53 tumors presenting a polysomal-like aneusomy for centromere 17, this is a phenomenon already described in breast cancers for which the clinical impact and effects on the expression of the HER2 protein are still uncertain [24].